A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery

Hemorrhage Clinical Trial

Official title:

A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01639833
• Other study ID #: COVEUCV0140
• Status: Completed
• Phase: N/A
• First received: July 11, 2012
• Last updated: June 3, 2014
• Start date: August 2012
• Est. completion date: December 2013

Study information

• Verified date: June 2014
• Source: Medtronic - MITG
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the safety and effectiveness of Veriset™ Hemostatic Patch in cardiovascular procedures by comparing Veriset™ Hemostatic Patch to TachoSil® in subjects undergoing open cardiovascular surgery involving the aorta (e.g., aortic valve replacement (AVR), David procedure, Bentall procedure, abdominal aortic aneurysm repair, etc.), or CABG.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject has provided informed consent.

• Subject is =18 years of age.

• Subject is scheduled for surgery involving the aorta (e.g., aortic valve replacement (AVR), David procedure, Bentall procedure, abdominal aortic aneurysm repair, etc.), or coronary artery bypass graft (CABG) where a topical hemostatic agent would be used to control bleeding via an open approach.

• Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.

• Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death.

• Subject has a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin.

• Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding.

• Subject has an estimated life expectancy of less than 6 months.

• Subject is unwilling to receive blood products.

• Subject is scheduled for another planned cardiovascular surgery, and subsequent surgery would jeopardize previous application of study treatment.

• The subject has participated in another investigational drug or device research study within 30 days of enrollment.

Exclusion Criteria:

• Subject has an appropriate Target Bleeding Site (TBS) defined as an area of bleeding on the aorta or coronary vessels where hemostasis by conventional methods is ineffective or impractical, and thus necessitates the use of a topical hemostatic agent.

• TBS Bleeding is Type 2 (Oozing/Mild) or 3 (Moderate).

• It is possible to hold pressure on Veriset™ Hemostatic Patch or TachoSil® for at least 3 minutes.

• Incidental finding of any other pre-operative exclusion criteria

• Subject does not have an appropriate TBS.

• TBS Bleeding Assessment is Type 1 (No bleeding) or 4 (Severe/Surgical/Life Threatening).

• Subject has an active local infection at the surgical site.

• Investigator determines that participation in the study may jeopardize the safety or welfare of the subject.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cardiac Surgical Procedures
• Hemorrhage

Intervention

Device:
• Veriset Hemostatic Patch
Topical hemostat
• TachoSil®
Topical Hemostat

Locations

Country	Name	City	State
Belgium	St Luc Hospital	Brussels
Belgium	UZ Brussels	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic - MITG

Countries where clinical trial is conducted

Belgium,  Germany,  Latvia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Hemostasis (TTH)	Time to Hemostasis (TTH) at the target bleeding site (TBS) following treatment (Veriset™ Hemostatic Patch or Control).	Day 0	No
Secondary	Hemostasis at All Treated Bleeding Sites Within 3 Minutes	The proportion of subjects achieving hemostasis at all treated bleeding sites within 3 minutes of device application.	Day 0	No